The new-generation acetylcholinesterase inhibitor, donepezil, is useful in the treatment of mild-to-moderate Alzheimer's disease. A 72-year-old male chronic hemodialysis patient was diagnosed as having moderate Alzheimer's disease. We administered donepezil at 3 mg/day orally to the patient. After 1 month's treatment, the patient improved to a controllable psychiatric condition and was discharged from the hospital. The 24-hour plasma concentration profile of donepezil following the 3-mg once-daily dose varied from 11.1 to 18.2 ng/ml. The through level of donepezil was reduced from 12.4 to 10.9 ng/ml over a 3-month period. We did not experience any episodes of drug toxicity or adverse effects in this chronic dialysis patient. Donepezil treatment might have a beneficial impact on patients with severe renal dysfunction.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000058413DOI Listing

Publication Analysis

Top Keywords

donepezil treatment
12
alzheimer's disease
12
acetylcholinesterase inhibitor
8
inhibitor donepezil
8
chronic dialysis
8
dialysis patient
8
donepezil
6
patient
5
treatment
4
treatment alzheimer's
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!